drugset / Trial / NCT00264953

HD11 for Intermediate Stages

NCT00264953 ↗

Phase 3 Completed 1395 enrolled University of Cologne
RandomizedFactorialOpen-labelTreatment

Summary

This study is designed to (1) compare the efficacy of the BEACOPP regimen with that of ABVD as a 4-cycle chemotherapy combined with an involved field irradiation and (2) to define the optimum radiation dose comparing of 30 to 20 Gy in the same context.

Timeline

Start
1998-05
Primary completion
2003-01
Completion
—

Outcome

Mixed primary results

paper after four cycles of BEACOPP(baseline), 20 Gy was not inferior to 30 Gy PMID 20713848 ↗

paper whereas inferiority of 20 Gy cannot be excluded after four cycles of ABVD PMID 20713848 ↗

Drugs

EvaluationDrugModalityDoseRoute
Subject Dacarbazine Small molecule — —
Subject Etoposide Small molecule — —
Subject Prednisone Other / unclassified — —
Subject Vinblastine Small molecule — —
Subject Vincristine Small molecule — —
Subject procarbazine Small molecule — —
Background Bleomycin Unknown — —
Background Doxorubicin Other / unclassified — —

Indications